Product category:
Nucleic acid sequencing and synthesis
News Release from: Bio-Rad Laboratories
Edited by the Laboratorytalk Editorial
Team on 11 May 2006
Bio-Rad revenues grow
Bio-Rad Laboratories, a manufacturer and distributor of life science research products and clinical diagnostics, announced financial results for the first quarter ended 31 March 2006
First-quarter revenues from continuing operations were $308.3 million, up 3.0% compared to the $299.2 million reported for the first quarter of 2005 On a currency-neutral basis, revenues increased 8.3% compared to the first quarter of 2005
This article was originally published on Laboratorytalk on 19 Feb 2002 at 8.00am (UK)
Related stories
Fully automated BSE testing system
New tests and automated platform promise to increase efficiency, produce faster results, expand mass screening capabilities, and reduce costs
New length for immobilized pH gradient strips
Bio-Rad Laboratories has added 18 cm IPG (immobilized pH gradient) strips to its popular ReadyStrip product line for the first dimension of 2-D gel electrophoresis
This sales increase was the result of organic growth across a broad array of product areas.
For the quarter, income from continuing operations was $31.2 million compared to $29.5 million in the same period last year.
At 56.9%, first-quarter gross margin from continuing operations was markedly higher than the 55.6% reported for the first quarter of 2005.
Further reading
Protein standards deliver even sharper bands
Precision Plus Protein standards deliver even sharper bands, more bands, superior lot-to-lot consistency and a dual color option in a broad range ladder
Improved performance from IPG strips
Bio-Rad Laboratories has developed an innovative line of Micro-Range ReadyStrip IPG strips which delivers higher resolution over a broader pH range
Entire line of agarose powders upgraded
Bio-Rad Laboratories has upgraded its entire line of agarose powders for nucleic acid electrophoresis.
The higher margin was due to a combination of improved efficiencies and certain non-recurring items.
First-quarter basic earnings from continuing operations were $1.19 per share, or $1.16 per share on a diluted basis, compared to $1.14 and $1.11, respectively, in the same period of last year.
Life Science segment net sales from continuing operations for the quarter were $144.8 million, up slightly from the $144.1 million reported last year.
Normalizing for the impact of currency effects, sales in this area increased by 5.6%.
The Clinical Diagnostics segment reported solid growth in its core businesses with net sales of $160.3 million, a 5.5% increase over the comparable period last year.
On a currency-neutral basis, segment sales increased 10.9% over the first quarter of 2005.
In February, the company reached a settlement agreement with Applera and Roche, enabling the company to resume US sales of certain MJ Research thermal cycling products.
Early in the quarter, Bio-Rad announced that it renewed a collaboration agreement with the Institut Pasteur of Paris for an additional four years.
This relationship gives Bio-Rad exclusive commercialization rights to Pasteur's developments in the areas of virology, microbiology, physiology, biochemistry, parasitology and mycology.
Life Science segment net sales for the quarter were $144.8 million, up 0.5% compared to the first quarter of last year.
On a currency-neutral basis, sales increased by 5.6%.
Performance in this segment was the result of a combination of factors including sales increases in the amplification reagents and instrumentation, automated electrophoresis and process chromatography product areas.
In particular, the segment benefited from a resumption of US sales of certain thermal cycling products as well as from continued penetration into the bio-pharmaceutical drug separation market with products such as Bio-Rad's Macro-Prep support used in the purification of inhalable insulin.
Segment performance was somewhat tempered, however, by a reduction in BSE testing revenue.
The Clinical Diagnostics segment reported net sales of $160.3 million for the quarter, up 5.5% compared to the prior-year quarter, or 10.9% excluding currency effects.
These results are due in part to continued growth in the blood typing, blood virus screening, autoimmune testing and diabetes monitoring product lines.
Following the placement of a substantial number of systems last year, reagent sales associated with the Company's Evolis automated microplate processors were up dramatically for the quarter.
In addition, sales to low- and mid-volume customers in the diabetes monitoring market benefited from the March release of the company's new Rack Loader for use in conjunction with the D-10 hemoglobin testing system, expanding the sample handling capacity of the system to 50 samples.
These benefits were partially offset, however, by increased competition in the high-volume segment of the market.
"The year is getting off to an excellent start, with sales in most regions meeting or exceeding expectations," said Norman Schwartz, president and chief executive officer. Request free introductory details about products from Bio-Rad Laboratories ...
"As the year unfolds, we will continue to work on a number of projects aimed at growing our core businesses and improving operational efficiency over the longer term.".
• Bio-Rad Laboratories: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
